Total Funding
29
69
Total FundingPost-IPO Equity raised
Growth Score
1 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
180792
Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit.
- Dan A. Peisert: President, Chief Executive Officer & Director
About the Company
Depomed is a specialty pharmaceutical company that strives to put the patient first in all that they do. Its mission is to improve the lives of patients, families, physicians, providers, and payors by commercializing pain and neurology products and developing drugs for unmet medical needs.
Depomed's Neurology and Pain Business currently
markets three medicines focused on neuropathic pain and migraine, and it has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need.
